SI-BONE Stock (NASDAQ:SIBN), Trade Ideas

SI-BONE

SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

Analyst Color

Equities

News

Price Target

Reiteration

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

SIBN

Needham analyst David Saxon reiterated a Buy rating on SI-BONE, Inc (NASDAQ: SIBN), 

SI-BONE Poised For A Surge: Analyst Highlights Upside Potential With New Product Launches

Earnings

Penny Stocks

Eurozone

Commodities

Global

Intraday Update

CHGG

CIGI

IMTX

UBER

VSEC

U.S. stocks traded lower this morning even as the Federal Reserve’s two-day meeting began.

Following the market opening Tuesday, the Dow traded down 0.47% to 33,891.31 while the NASDAQ fell 0.12% to 12,197.84. The S&amp;P 500 also declined, losing 0.37% to 4,152.34.

US Stocks Down; Chegg Crashes After Removing Guidance On ChatGPT Concerns

Guidance

Health Care

Movers

Analysts Remain Bullish On SI-BONE, Forecast Q4&#39;s Strength To Continue In 2023

SI-BONE Inc

Analysts have been eager to weigh in on the Healthcare sector with new ratings on CSL (CMXHF – Research Report), Aurora Cannabis (ACB – Research Re...

Analysts Have Conflicting Sentiments on These Healthcare Companies: CSL (OtherCMXHF), Aurora Cannabis (ACB) and SI-Bone (SIBN)

In a report released today, Samuel Brodovsky from Truist Financial reiterated a Buy rating on SI-Bone (SIBN – Research Report), with a price target...

Truist Financial Sticks to Its Buy Rating for SI-Bone (SIBN)

In a report released today, Ross Osborn from Cantor Fitzgerald reiterated a Buy rating on SI-Bone (SIBN – Research Report), with a price target of ...

SI-Bone (SIBN) Gets a Buy from Cantor Fitzgerald

Tuesday, February 27, 2024 - Si-Bone Inc (SIBN) reported upside earnings and revenues today.Si-Bone Inc's earnings came in at an EPS loss of $0.27 per share, 4.00% higher than estimates for an EPS loss of $0.28 per share. The firm's loss per share narrowed by 16% since reporting a loss of $0.32 per share a year ago. Consen

Si-Bone Inc Down 11.88% To $18.10 After Earnings Beat

These Healthcare stocks are trading higher:-Janux Therapeutics Inc (JANX) stock is trading at $46.54, a gain of $31.44, or 211.39%, on high volume.  Janux Therapeutics Inc gets a Sentiment Score of Neutral from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $26.67. Jan

Healthcare Stocks Making Moves Tuesday: JANX, VKTX, BIOR, CTMX, NERV, PRGO, CMAX, SIBN

Bank of America Securities analyst Craig Bijou reiterated a Buy rating on SI-Bone (SIBN – Research Report) today and set a price target of $26.00. ...

Buy Rating Affirmed for SI-Bone on Expansion and Market Growth Strategies

SI-Bone (SIBN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Saxon from Needham rei...

SI-Bone's Favorable Outlook and Buy Rating Amidst Stable Medical Coverage and Growth Prospects

Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down

Truist Financial analyst Samuel Brodovsky maintained a Buy rating on SI-Bone (SIBN – Research Report) yesterday and set a price target of $20.00. T...

Truist Financial Sticks to Their Buy Rating for SI-Bone (SIBN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on SI-Bone (SIBN – Research Report), Conmed (CNMD – Research Report)...

Analysts' Opinions Are Mixed on These Healthcare Stocks: SI-Bone (SIBN), Conmed (CNMD) and Chemed (CHE)

AORT

ATEC

ATRC

AZTA

BIOR

CMAX

CMXHF

CNMD

CTMX

ENOV

GKOS

IRTC

ISRG

JANX

KIDS

LIVN

NARI

NERV

PRGO

RXST

SRDX

VCYT

VKTX

XRAY

Press Releases

SI-BONE to Report Third Quarter 2023 Financial Results on November 6, 2023

SI-BONE To Present at Jefferies London Healthcare Conference on November 15, 2023

SI-BONE, Inc. Reports Record Financial Results for the Third Quarter 2023  and Raises Annual Guidance

SI-BONE To Present at Piper Sandler 35th Annual Healthcare Conference on November 28, 2023

SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2023

SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application

SI-BONE To Report Fourth-Quarter and Full-Year 2023 Financial Results on February 26, 2024

SI-BONE, Inc. Reports Record Fourth Quarter and Full Year 2023 Financial Results and Issues 2024 Guidance

SI-BONE to Present at Barclays 26th Annual Global Healthcare Conference on March 12, 2024